BioSpace News Archive

Deals

BioLife Solutions Joins S&P SmallCap 600 Index

BioLife Solutions , Inc. today announced that its common stock will be added to the S&P SmallCap 600 Index effective prior to the opening of trading on Monday, August 30, 2021.

August 25, 2021
·
2 min read
Business

BioStem Technologies Reports Record Breaking Second Quarter Sales

BioStem Technologies, Inc. today reported financial results for three and six months ended June 30, 2021.

August 25, 2021
·
5 min read
Pathogen Reduction System Market Global Industry Growth, Size, Share, COVID-19 Impact Analysis, Trends and Forecasts Report 2028

Pathogen reduction systems are widely used to inactivate viruses and bacteria that may contaminate blood products.

August 25, 2021
·
5 min read
Drug Development

Servier and OSE Immunotherapeutics Announce Enrollment of First Patient in OSE-127/S95011 Phase 2 Clinical Trial in Sjögren’s Syndrome

Servier, an independent global pharmaceutical group, and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE), a French biotech, have announced enrollment of the first patient in the Phase 2 clinical trial of OSE-127/S95011 in Sjögren’s syndrome, with Servier sponsorship.

August 25, 2021
·
7 min read
Genetown

Tasrif Pharmaceutical Announces Grant of U.S. Patent for Humanized Monoclonal Antibodies against the Poliovirus Receptor

Tasrif Pharmaceutical announces the grant of a US Patent related to its proprietary humanized monoclonal antibodies against the poliovirus receptor (a.k.a. CD155). Poliovirus Receptor (PVR) is overexpressed on many malignancies including cancers of the brain, breast, colon and pancreas.

August 25, 2021
·
2 min read
Drug Development

Ryvu Announces First Patient Dosed in Phase I/II Study of RVU120 (SEL120) in Patients with Relapsed/Refractory Metastatic or Advanced Solid Tumors and CMO Transition

Ryvu Therapeutics (WSE: RVU) announced today that the first patient enrolled in the Phase I/II clinical trial investigating RVU120 (SEL120) in relapsed/refractory metastatic or advanced solid tumors, has received the first dose of the study drug.

August 25, 2021
·
6 min read
Drug Development

AB Science announces that it has received a second authorization to resume patient enrollment, in the Phase 3 study of masitinib in mastocytosis

AB Science SA (Euronext - FR0010557264 - AB) announced today that it has received authorization from the French National Agency (ANSM) to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB15003) in mastocytosis.

August 25, 2021
·
5 min read
Biotech Bay

Presidio Medical™ Announces Publication of ULF™ Neuromodulation Research in Science Translational Medicine

Presidio Medical, Inc., a clinical-stage medical technology company developing a transformational neuromodulation platform, today announced research involving the company’s novel ULF™ neuromodulation therapy has been published in Science Translational Medicine.

August 25, 2021
·
2 min read
Biotech Beach

Opiant Pharmaceuticals to Participate in September 2021 Investor Conferences

Opiant Pharmaceuticals, Inc. announced that members of the company’s senior management team will participate in the following virtual investor conferences

August 25, 2021
·
1 min read
Policy

BioCryst Announces Acceptance of Regulatory Applications for ORLADEYO® (berotralstat) by Health Canada and Swissmedic

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the new drug submission for ORLADEYO® (berotralstat) has been accepted for review by Health Canada for the prevention of recurrent attacks in patients with hereditary angioedema (HAE) 12 years and older.

August 25, 2021
·
6 min read